# Liposomal Irinotecan, Fluorouracil, Leucovorin Calcium, and Rucaparib in Treating Patients With Metastatic Pancreatic, Colorectal, Gastroesophageal, or Biliary Cancer

> **NCT03337087** · PHASE1,PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Academic and Community Cancer Research United** · enrollment: 18 (actual)

## Conditions studied

- Metastatic Biliary Tract Carcinoma
- Metastatic Colorectal Carcinoma
- Metastatic Gastroesophageal Junction Adenocarcinoma
- Metastatic Malignant Digestive System Neoplasm
- Metastatic Pancreatic Adenocarcinoma
- Stage IV Colorectal Cancer AJCC v7
- Stage IV Pancreatic Cancer AJCC v6 and v7
- Stage IVA Colorectal Cancer AJCC v7
- Stage IVB Colorectal Cancer AJCC v7

## Interventions

- **DRUG:** Fluorouracil
- **DRUG:** Irinotecan Sucrosofate
- **OTHER:** Laboratory Biomarker Analysis
- **DRUG:** Leucovorin Calcium
- **DRUG:** Rucaparib

## Key facts

- **NCT ID:** NCT03337087
- **Lead sponsor:** Academic and Community Cancer Research United
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2018-11-02
- **Primary completion:** 2021-03-31
- **Final completion:** 2025-08-09
- **Target enrollment:** 18 (ACTUAL)
- **Last updated:** 2024-05-17

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03337087

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03337087, "Liposomal Irinotecan, Fluorouracil, Leucovorin Calcium, and Rucaparib in Treating Patients With Metastatic Pancreatic, Colorectal, Gastroesophageal, or Biliary Cancer". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT03337087. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*